No side effects, effective for 24 hours: A new discovery from scientists that will make you throw away painkillers!

Scientists from Kindai University in Japan have made a breakthrough discovery that will revolutionize pain treatment. A new antibody that targets cell adhesion molecule 1 (CADM1), 3E1, is drawing attention with its long-lasting and side-effect-free pain-relieving effect.

Japanese scientists have discovered a new antibody that offers long-lasting and side-effect-free pain-relieving effect.
The antibody called 3E1 targets the CADM1 protein on the surface of nerve cells and affects only sensory nerves. In this way, it suppresses pain signals without leaving a negative effect on motor nerves.
Prof. Akihiko Ito and Dr. The study, led by Fuka Takeuchi, was published in the scientific journal Life Sciences.
As part of the research, the 3E1 antibody was injected into the skin of mice. It was observed that the antibody was localized only in sensory nerves under the skin.
In chemical-induced pain tests, it was observed that pain symptoms were significantly reduced in mice treated with 3E1 compared to the control group.
Moreover, these effects lasted much longer than existing local anesthetics, up to 24 hours.
According to the research team, the biggest advantage of 3E1 is that it does not have a negative effect on motor nerves.
In the experiments, it was determined that the antibody did not cause paralysis or behavioral disorders. Prof. “This antibody, which accumulates in the nerves with an injection and provides a pain-relieving effect, may open the door to a new field of medicine called ‘antibody anesthetics,’” Ito said.
In recent years, antibody-based drugs used to treat osteoarthritis and chronic pain have had limited success due to their serious side effects. However, 3E1 offers a safe solution without creating toxic effects.
Researchers continue to work on longer-lasting versions of the antibody for use in humans. This innovative treatment holds great promise for chronic pain and other pain-related disorders.
Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use